Scope and claims for U.S. Patent 8,946,251 (paroxetine 7.5 mg/day for menopause thermoregulatory dysfunction)
U.S. Patent 8,946,251 claims a method of treating menopause-associated thermoregulatory dysfunction by administering paroxetine at a specific daily exposure: 7.5 mg/day “based on the paroxetine moiety.” Claim scope centers on dose and the therapeutic indication, then expands through optional limitations on drug form (free base, salt, hydrate/anhydrate/solvate, crystalline/amorphous). The estate is claim-structured to support enforcement against any FDA-legal paroxetine product that practices the claimed regimen, even if the formulation differs within the enumerated categories.
What does U.S. Patent 8,946,251 claim in plain terms?
Core claimed invention
- A method for treating a patient with thermoregulatory dysfunction associated with menopause.
- The method requires administering a dosage form of paroxetine at 7.5 mg/day.
- The dose is defined “based on the paroxetine moiety.” That phrasing is designed to standardize the salt/formulation and capture equivalent paroxetine content across different salt forms.
Indication scope
- The claimed thermoregulatory dysfunction includes hot flashes, hot flushes, night sweats, and combinations.
Claim dependency behavior
- Claim 1 is the only independent claim provided in the user-supplied excerpt.
- Claims 2–12 are dependent claim fallbacks that narrow the independent method by specifying the clinical manifestation and/or the physical drug form.
How broad is the independent claim 1 for 7.5 mg/day paroxetine?
Claim 1 scope (from the provided text)
- Applies to any patient suffering from menopause-associated thermoregulatory dysfunction.
- Requires paroxetine in a dosage form.
- Requires 7.5 mg/day based on paroxetine moiety.
What claim 1 likely captures
- Paroxetine products (not limited to a particular salt or base form) if they dose to 7.5 mg/day paroxetine moiety.
- Methods implemented using oral paroxetine dosage forms that can be measured to the daily moiety amount.
What claim 1 likely does not require
- No explicit specification of: formulation type (tablet, capsule, etc.), release profile, route (implied by “dosage form”), or particular paroxetine salt unless narrowed via dependent claims.
Key enforcement lever
- The 7.5 mg/day moiety dose definition is the primary boundary. It is the first-order feature that an infringing regimen must match.
What thermoregulatory dysfunctions are explicitly covered by the claims?
Claim 2 (dependent)
- Limits to conditions selected from:
- hot flashes
- hot flushes
- night sweats
- combinations thereof
Practical consequence
- In litigation, “thermoregulatory dysfunction associated with menopause” is supported by enumerated clinical manifestations. The presence of any of the listed symptoms can map a patient case to dependent claim language once the regimen is otherwise established.
Which paroxetine forms are claimed (free base vs salt vs solvates)?
The user-supplied claims treat “dosage form” as a structural platform. The dependent claim set enumerates multiple categories that can function as separate infringement theories.
Free base
- Claim 3: dosage form comprises paroxetine free base.
Paroxetine salts (broad list, then narrower groupings)
-
Claim 4: dosage form comprises a pharmaceutically acceptable salt of paroxetine.
-
Claim 5: salt selected from
- hydrohalides
- sulfates
- phosphates
- oxalate
- tosylate
- pamoate
- citrate
- carbonate
- bicarbonate
- maleate
- malate
- fumarate
-
Claim 6: further narrows hydrohalides to:
- hydrochloride
- hydrobromide
- hydroiodide
- combinations
-
Claim 7: narrows to sulfate and bisulfate and combinations.
-
Claim 8: narrows to mono-, di-, tri-basic phosphates and combinations.
Practical consequence
- If a commercial product uses paroxetine hydrochloride, paroxetine sulfate/bisulfate, or one of the specified phosphate forms, it fits at least one dependent claim. If a product uses a salt outside those enumerated exemplars but still qualifies as a “pharmaceutically acceptable salt,” claim 4 may still be argued.
Hydrate/anhydrate/solvate
- Claim 9: dosage form comprises paroxetine or paroxetine salt in:
- anhydrate
- hydrate
- solvate
- or combinations
Crystalline vs amorphous
-
Claim 10: paroxetine or paroxetine salt in:
- crystalline or amorphous form
- or combinations
-
Claim 11: specifies crystalline.
-
Claim 12: specifies amorphous.
Practical consequence
- The dependent claim set is designed to avoid a formulation “escape.” It creates multiple independent landing points for generic or branded challengers to address different solid-state properties.
Where is the main claim boundary: dose, indication, or formulation?
Dose and indication dominate
- Claim 1 binds to:
- the thermoregulatory dysfunction associated with menopause
- and the 7.5 mg/day paroxetine moiety dose.
Formulation is secondary and mostly a fallback
- Dependent claims 3–12 largely recite drug form characteristics.
- The independent claim 1 does not require a specific salt or solid form in the provided text. That means formulation changes should not avoid claim 1 if the regimen still administers 7.5 mg/day paroxetine moiety.
Litigation posture
- A plaintiff would typically argue:
- clinical mapping to menopause thermoregulatory dysfunction,
- prescribed/administered regimen equals 7.5 mg/day paroxetine moiety,
- dosage form fits at least one dependent claim if needed as additional narrowing.
How many distinct “claim pathways” exist in the dependent set?
From the provided claims, at minimum there are distinct formulation pathways:
- Free base (Claim 3)
- Any pharmaceutically acceptable salt (Claim 4)
- Enumerated salt exemplars (Claim 5)
- Hydrohalide salts (Claim 6)
- Sulfate/bisulfate (Claim 7)
- Mono/di/tri-basic phosphates (Claim 8)
- Anhydrous/hydrate/solvate (Claim 9)
- Crystalline/amorphous (Claims 10–12)
Combined with Claim 2’s symptom types, the dependent structure supports multiple infringement theories without altering the dose and indication core.
What is the strategic scope for a generic trying to avoid infringement?
Given only the provided claim language, avoidance must target one of the three claim elements:
- Paroxetine moiety dose
- Menopause-associated thermoregulatory dysfunction
- Paroxetine as the administered active
Dose carve-outs
- The claims as written are anchored to 7.5 mg/day. Changing to other paroxetine daily doses would not fit claim 1’s numerical requirement.
Indication/label carve-outs
- If a generic product were positioned strictly for a different indication or if prescribing diverges from menopause thermoregulatory dysfunction, infringement may fall away. However, the claims are directed to “method for treating a patient suffering from” the relevant dysfunction, so off-label use risks remain depending on how evidence is gathered.
Active ingredient carve-outs
- Using a different SSRI or different molecule generally avoids these claims because the method requires paroxetine.
Formulation changes
- The dependent claims broadly enumerate forms, including multiple salts and solid states. Changing among those categories likely does not avoid the core method and may still satisfy dependent limitations.
How does this claim set compare with typical paroxetine fixed-dose method patents?
Typical pattern
- Many method patents for drug repositioning or dose-based regimens use:
- an indication definition,
- a specific dosing parameter,
- and optionally dosage-form and/or solid-state descriptors as claim narrowing.
This patent’s distinctive enforcement posture
- The provided dependent claims heavily enumerate:
- paroxetine salt families, including hydrohalides and phosphate species,
- hydrate/anhydrate/solvate conditions,
- crystalline/amorphous states.
- That breadth in formulation descriptors reduces the ability for a generic to avoid the method by changing salt selection or solid-state form, as long as the moiety dose remains 7.5 mg/day.
What litigation and regulatory questions are answerable from the claim text alone?
Paragraph IV and FDA Orange Book status
- Not determinable from the provided information. Claim text alone does not establish:
- whether the patent is listed for a specific NDA/BLA,
- relevant Orange Book codes,
- or whether claims are method-of-use versus drug-substance/drug-product.
- Those are tied to FDA listing data and legal records not included in the provided prompt.
Expiration and exclusivity timelines
- Not determinable from the provided information. Expiration depends on:
- filing date,
- prosecution history,
- patent term adjustments,
- and any patent term extensions.
Settlement agreement coverage
- Not determinable from the provided information. Settlement terms require litigation docket data.
Accordingly, this analysis focuses on claim scope and how it maps to potential infringement scenarios.
Key Takeaways
- U.S. Patent 8,946,251 is a dose-anchored method patent: it requires paroxetine at 7.5 mg/day based on the paroxetine moiety for menopause-associated thermoregulatory dysfunction.
- The primary claim boundary is the combination of indication + exact daily moiety dose; formulation details are mostly dependent fallbacks that expand coverage across many salt and solid-state forms.
- Dependent claims enumerate free base, numerous pharmaceutically acceptable salts, hydrochloride/hydrobromide/hydroiodide, sulfate/bisulfate, mono/di/tri-basic phosphates, and anhydrate/hydrate/solvate plus crystalline/amorphous forms.
- For design-around, the practical lever is to avoid the 7.5 mg/day moiety regimen or to avoid paroxetine or the claimed menopause thermoregulatory dysfunction treatment context; simple formulation switching within the enumerated categories is unlikely to remove infringement exposure.
FAQs
1) Does U.S. Patent 8,946,251 cover paroxetine hydrochloride specifically?
Yes. Claim 6 includes paroxetine hydrochloride (and hydrobromide/hydroiodide and combinations), all within the 7.5 mg/day method framework.
2) Is the patent limited to hot flashes only?
No. Claim 1 covers thermoregulatory dysfunction associated with menopause, and Claim 2 specifies hot flashes/hot flushes/night sweats and combinations.
3) Can a different paroxetine salt avoid infringement of claim 1?
Claim 1 does not require a specific salt in the provided text. If the product delivers 7.5 mg/day based on the paroxetine moiety for the same indication, changing the salt alone is unlikely to avoid claim 1.
4) Are crystalline and amorphous solid states covered?
Yes. Claims 10–12 cover crystalline and amorphous forms, including combinations.
5) What is the main design-around parameter for generic developers?
The most direct design-around is changing the paroxetine daily exposure away from 7.5 mg/day based on paroxetine moiety or avoiding the claimed therapeutic use context.
